Insider trading of Christopher J Coughlin, a Director at AGN Allergan plc.
Most recently Christopher J Coughlin bought 10,000 shares worth $1,633,000.00 on 5 December 2017.
About Allergan plc.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
- Allergan plc., Clonshaugh Business and Technology Park, Dublin D17 E400, Ireland
- 862 261 7000
Insider trading of Christopher J Coughlin, a Director at ALXN Alexion Pharmaceuticals, Inc.
Most recently Christopher J Coughlin bought 2,000 shares worth $234,200.00 on 15 June 2017.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
- Alexion Pharmaceuticals, Inc., 100 College Street, New Haven 06510, United States
Insider trading of Christopher J Coughlin, a Director at DNB Dun & Bradstreet Corporation (The)
Most recently Christopher J Coughlin exercised 2,086 shares worth $183,651.44 on 26 January 2017.
The Dun & Bradstreet Corporation provides commercial data, analytics, and insights on businesses worldwide. It offers risk management solutions, including DNBi and D&B Credit, which are subscription based online applications that provide customers real time access to global information, monitoring, and portfolio analysis; various business information reports; D&B Direct, an application programming interface that enables data integration inside enterprise resource planning applications, and master data management and toolkit; credit monitoring solutions; Supplier Risk Manager, an online application, which helps businesses to mitigate supply chain risk; and Onboard and Compliance Check that are online applications that help customers comply with anti-money laundering. The company also offers sales and marketing solutions, such as customer data management solutions to clean, identify, link, and enrich customer information; D&B Optimizer solution that transforms customer prospects and data into commercial insight; Hoover's that provides information on public and private companies, industries and executives, sales, and marketing and research professionals; Market Insight tools that enable customers to understand existing customers in order to create campaigns to cross-sell new business; Audience Solutions, which enable advertisers and companies to target professionals in various ways; and various other marketing solutions. It serves customers in communication, technology, government, strategic financial service, and retail/telecommunications/manufacturing markets. The Dun & Bradstreet Corporation was founded in 1841 and is headquartered in Short Hills, New Jersey.
- Dun & Bradstreet Corporation (The), 103 JFK Parkway, Short Hills 07078, United States